1 recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
Follow REC617: new trials by email Literature Review of REC617 trials Research Report on REC617
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy REC617 - Phase 1b, Open Label | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 15 | 2026-10-19 | 2026-07-31 |
Leiomyosarcoma (1)
M.D. Anderson Cancer Center (1)
United States (1)
Elise Nassif, MD (1)